Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: May 24, 2011
Last updated: November 30, 2012
Last verified: November 2012
This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.

Condition Intervention Phase
Drug: LFF269
Drug: Eplerenone
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change from baseline in mean 24-hour systolic blood pressure (SBP) as measured by ambulatory blood pressure monitoring (ABPM) after 4 weeks treatment [ Time Frame: Baseline, week 4 ]

Secondary Outcome Measures:
  • Change from baseline in mean 24-hour diastolic blood pressure (DBP) as measured by ABPM after 4 weeks of treatment [ Time Frame: Baseline, week 4 ]
  • Change from baseline in mean 24-hour SBP and DBP as measured by ABPM after 4 weeks treatment [ Time Frame: Baseline, week 4 ]
  • Percentage of patients experiencing adverse events during the study as measure of safety and tolerability [ Time Frame: 4 weeks ]
    Adverse events will be reported as percentage of patients with total adverse events, serious adverse events and death.

  • Change from baseline in mean sitting SBP and DBP after 4 weeks treatment [ Time Frame: Baseline, week 4 ]
  • Percentage of patients achieving a successful BP response (> placebo) and BP control (SBP < 140 mmHg at trough) [ Time Frame: 4 weeks ]
  • change from baseline in mean daytime and mean nighttime SBP and DBP as measured by ABPM after 4 weeks treatment [ Time Frame: Baseline, week 4 ]
  • Pharmacokinetics of LFF269: Plasma concentrations of LFF269 [ Time Frame: pre dose & 6 hours post study drug dose ]

Enrollment: 19
Study Start Date: May 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LFF269 low dose
LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period
Drug: LFF269 Drug: Placebo
Experimental: LFF269 high dose
LFF269 high dose + Matching Placebo to Eplerenone 50mg
Drug: LFF269 Drug: Placebo
Active Comparator: Eplerenone
Eplerenone 50mg twice daily + matching placebo of LFF269
Drug: Eplerenone Drug: Placebo
Placebo Comparator: Placebo
Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg
Drug: Placebo


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female (post-menopausal or surgically sterile).
  2. Age from 18 to 75 years inclusive.
  3. Subjects with mild-to-moderate uncomplicated essential hypertension, with (not more than 2 in combination) or without prior treatment.
  4. Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 36 kg/m2.

Exclusion Criteria:

  1. History or evidence of a secondary form of hypertension,
  2. History of cardiovascular disease. Type 1 or type 2 diabetes mellitus.
  3. Clinically significant valvular heart disease.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01373086

United States, California
Advanced Clinical Research Institute-Phase I
Anaheim, California, United States, 92801
United States, Florida
Comprehensive Phase I
Fort Myers, Florida, United States, 333901
Comprehensive Phase One®,
Miramar, Florida, United States, 33025
Comprehensive NeuroScience
St Petersburg, Florida, United States, 33716
United States, Georgia
Clinical Research Atlanta
Stockbridge, Georgia, United States, 30281
United States, Nebraska
Clinical Research Advantage/ Prairie Fields Family Medicine, PC
Fremont, Nebraska, United States, 68025
Internal Medicine Physicians
Omaha, Nebraska, United States, 68130
ICON Developmental Solutions
Omaha, Nebraska, United States, 68154
United States, Nevada
Clinical Research Advantage/ Aloha Medical
Las Vegas, Nevada, United States, 89183
United States, Texas
ICON Development Solutions,
San Antonio, Texas, United States, 78209
United States, Washington
Comprehensive Clinical Development NW, Inc.
Tacoma, Washington, United States, 98418
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01373086     History of Changes
Other Study ID Numbers: CLFF269X2201
Study First Received: May 24, 2011
Last Updated: November 30, 2012

Keywords provided by Novartis:
mild hypertension,
moderate hypertension,
high blood pressure,
uncomplicated hypertension.

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents processed this record on April 21, 2017